Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel
recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib in patients with advanced liposarcoma and DDLPS
Query: C.1-liposarcoma.json PK: cad54791-6616-4d89-97e0-83af40ad2e14 Control: https://pubmed.ncbi.nlm.nih.gov/?term=liposarcoma+chemotherapy&filter=pubt.review result #3: https://pubmed.ncbi.nlm.nih.gov/32026050/
Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel
recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib in patients with advanced liposarcoma and DDLPS
Results Tracking Sheet